Immatics FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Immatics (NASDAQ:IMTX - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Immatics in a research report issued to clients and investors on Tuesday, April 1st. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings per share of ($1.53) for the year, down from their prior estimate of ($1.34). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Immatics' current full-year earnings is ($0.72) per share.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The firm had revenue of $15.67 million during the quarter, compared to analysts' expectations of $16.16 million.

Immatics Stock Down 3.0 %

IMTX stock traded down $0.11 during trading on Thursday, reaching $3.57. The company's stock had a trading volume of 447,366 shares, compared to its average volume of 641,685. The company's fifty day moving average is $4.78 and its 200-day moving average is $7.07. The company has a market capitalization of $426.10 million, a P/E ratio of -5.41 and a beta of 0.85. Immatics has a 1 year low of $3.30 and a 1 year high of $13.77.

Institutional Trading of Immatics

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC lifted its holdings in shares of Immatics by 34.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after buying an additional 2,479 shares in the last quarter. Quarry LP boosted its position in shares of Immatics by 29.4% during the third quarter. Quarry LP now owns 11,000 shares of the company's stock worth $126,000 after acquiring an additional 2,500 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Immatics by 24.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock valued at $163,000 after acquiring an additional 4,477 shares in the last quarter. Finally, Forefront Analytics LLC increased its holdings in Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after acquiring an additional 4,731 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company's stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.